A | B | C | D | E | F | G | H | CH | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9
INNA-051
| Clinical data | |
|---|---|
| Routes of administration | Intranasal |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
.svg){kind=small} COVID-19 portal |
INNA-051 is a COVID-19 vaccine candidate developed by Ena Respiratory.[1][2]
References
- ^ "INNA-051 intranasal safety and tolerability study". anzctr.org.au. 21 April 2021. ACTRN12621000607875p. Retrieved 20 May 2021.
- ^ Clinical trial number NCT05118763 for "Intranasal INNA-051 for Prevention of COVID-19 in Adults" at ClinicalTrials.gov
Scholia has a profile for INNA-051 (Q110269792).
